Company intelligence / Profile preview

BioHybrid Solutions

Pittsburgh (Sharpsburg), Pennsylvania, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

BioHybrid Solutions is developing next-generation protein therapeutics called NanoArmored™ protein-polymer conjugates. Their most advanced drug, BHS-001, is being developed as a nerve agent prophylactic. The company has generated compelling data and built valuable infrastructure to support the deployment of their technology.

Therapeutic areas: OtherOncologyImmunologyMetabolic Disorders
Modalities: Protein therapeuticsprotein-polymer conjugatesbiologic drugs
Industry: Biotech

Partnerships

U.S. Department of Defense

Beyond the preview

Go deeper on BioHybrid Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioHybrid Solutions.

Explore the full profile